Lpath Inc.'s stock plunged 79.5 percent on word of the lead compound's phase II blowup, but "there exists some true assets that can be built upon," spokeswoman Pam Lord told BioWorld Today, and the company is restructuring to conserve money. Read More
Disclosure of promising top-line data from a phase II dose-optimization trial evaluating the therapeutic vaccine GEN-003 in genital herpes boosted shares of Genocea Biosciences Inc. (NASDAQ:GNCA) 8.8 percent Wednesday, aided by a price target hike from Piper Jaffray & Co. Read More
By equipping bacteriophages with the gene-editing system CRISPR, researchers have been able to sensitize drug-resistant bacteria to antibiotics. And by combining that sensitization with enhanced resistance to a second separate phage, the team was able to forestall the development of resistance against the first phage – which left the bacteria vulnerable to antibiotics but did not kill them outright. Read More
Defending patents for drugs and medical devices is part of the stakes of an R&D budget, but the size of that stake could increase significantly if a hedge fund manager wins his inter partes review (IPR) challenge of selected drug patents. Read More
HONG KONG – Not only is China's biotech sector growing fast, but it is also changing rapidly. And those changes in its basic structure are appealing to Asia-focused biotech investors who gathered this week at Asia Biotech Invest 2015. Read More
The FDA signed a five-year memorandum of understanding with the National Forum for Heart Disease and Stroke Prevention to promote a public education program to reduce the incidence of heart disease and stroke. Read More
Regenxbio Inc., of Rockville, Md. completed a heavily oversubscribed $70.5 million series D financing, bringing the total capital raised by the company since inception to more than $110 million. Regenxbio said it plans to use the proceeds to advance its lead programs through clinical development, build out its clinical and manufacturing infrastructure, expand its team and add to its current pipeline of adeno-associated viral vector-based gene therapies. Read More
Biomay AG, of Vienna, and contract research and development company VTU Technology, of Grambach, Austria, said they entered a licensing agreement for the production of recombinant allergens. Under the terms, Biomay will use VTU's Pichia expression strains for commercial production, with VTU receiving royalties based on Biomay´s worldwide sales of the recombinant allergens. Read More
Novartis AG, of East Hanover, N.J., presented data from its phase III EXPEDITION program at the American Thoracic Society meeting in Denver showing that QVA149 (indacaterol/glycopyrronium), at the 27.5/12.5 mcg dose, demonstrated statistically significant and clinically meaningful improvements in lung function at week 12 compared to its individual components and to placebo in patients with moderate to severe chronic obstructive pulmonary disease. Read More
Immunomic Therapeutics Inc., of Hershey, Pa., appointed Eric Winzer chief financial officer and Louise Peltier vice president of regulatory affairs. Read More
